First-In-Human Study of 211 At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies.
A new radioimmune therapy showed immediate cancer-killing activity in early human testing, though further work is needed to manage side effects safely.
This first-in-human phase 1 dose-finding trial evaluated Relapse is the dominant cause of failure after allogeneic hematopoietic cell transplantation (HCT) for aggressive hematologic malignancies. The authors report that in 45 adults, first-in-human astatine-211 anti-CD45 radioimmunotherapy showed immediate cytotoxic activity and could be incorporated into conditioning, although liver toxicity limited dosing.
What the study was
- Study design
- First-in-human phase 1 dose-finding trial
- Sample size
- 45
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
9/10: First-in-human phase 1 dose-finding trial with direct relevance to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; scoring remains conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.